Edition:
United Kingdom

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

7.75USD
6:07pm BST
Change (% chg)

$0.15 (+1.97%)
Prev Close
$7.60
Open
$7.62
Day's High
$7.75
Day's Low
$7.52
Volume
25,520
Avg. Vol
76,071
52-wk High
$66.60
52-wk Low
$5.20

Latest Key Developments (Source: Significant Developments)

Endologix Announces Reinstatement Of CE Mark For Its Nellix Endovascular Aneurysm Sealing System
Thursday, 6 Jun 2019 

June 6 (Reuters) - Endologix Inc ::ENDOLOGIX ANNOUNCES REINSTATEMENT OF CE MARK FOR ITS NELLIX ENDOVASCULAR ANEURYSM SEALING SYSTEM.ENDOLOGIX - DOES NOT EXPECT REINSTATEMENT OF CE MARK FOR ITS NELLIX ENDOVASCULAR ANEURYSM SEALING SYSTEM TO IMPACT PREVIOUSLY COMMUNICATED 2019 GUIDANCE.  Full Article

Endologix Reports Q1 Loss Per Share $2.12
Thursday, 2 May 2019 

May 2 (Reuters) - Endologix Inc ::ENDOLOGIX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $2.12.SEES Q2 2019 REVENUE ABOUT $36 MILLION.Q1 REVENUE $35.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $34.4 MILLION.SEES FY 2019 REVENUE AT LEAST $140 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-1.55 -- REFINITIV IBES DATA.CONTINUES TO EXPECT 2019 OPERATING EXPENSES IN RANGE OF $130 MILLION TO $140 MILLION.TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH WERE $10.9 MILLION AS OF MARCH 31, 2019, COMPARED TO $24.7 MILLION AS OF DECEMBER 31, 2018.Q2 REVENUE VIEW $35.3 MILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $141.2 MILLION -- REFINITIV IBES DATA.  Full Article

Endologix Says Unrestricted Sales And Use Of Nellix System Will Cease Immediately
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Endologix Inc ::ENDOLOGIX TAKES DECISIVE ACTION TO OPTIMIZE PATIENT OUTCOMES BY ENSURING NELLIX SYSTEM USED ONLY WITHIN CURRENT INDICATIONS.NO CHANGE TO PREVIOUSLY ISSUED REVENUE GUIDANCE FOR 2019.VOLUNTARY RECALL OF EXISTING INVENTORY, NEW CASES CONDUCTED UNDER CLINICAL PROTOCOL.NO CHANGE TO EVAS2 IDE.UNRESTRICTED SALES AND USE OF NELLIX SYSTEM WILL CEASE IMMEDIATELY.PRODUCT WILL ONLY BE AVAILABLE FOR USE UNDER CLINICAL PROTOCOL WITH PRE-SCREENED PATIENTS THAT ADHERE TO CURRENT INDICATIONS..FY2019 REVENUE VIEW $140.8 MILLION -- REFINITIV IBES DATA.  Full Article

Endologix Posts Q4 Loss Per Share $0.17
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - Endologix Inc ::ENDOLOGIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS.SEES FY 2018 GAAP LOSS PER SHARE $0.89 TO $0.95.Q4 LOSS PER SHARE $0.17.SEES FY 2018 REVENUE $170 MILLION TO $180 MILLION.Q4 REVENUE FELL 7.3 PERCENT TO $44 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.21, REVENUE VIEW $44.9 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $187.0 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $-0.50 -- THOMSON REUTERS I/B/E/S.  Full Article

Endologix Q3 loss per share $0.17
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Endologix Inc ::Endologix reports third quarter 2017 financial results.Sees FY 2017 gaap loss per share $0.91 to $0.93.Q3 loss per share $0.17.Sees FY 2017 revenue $181 million to $184 million.Q3 revenue $46 million versus I/B/E/S view $46.7 million.Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.  Full Article

Endologix says operations not materially affected by Santa Rosa fires‍​
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Endologix Inc : :Comments on impact of the Santa Rosa fires impact on co's facility ‍​.Co's Santa Rosa, California-based facility that manufactures and develops its ovation product line is safe and secure.Says it operations have not been materially affected by the Santa Rosa fires.Endologix Inc says it resumed shipments from its Santa Rosa facility on Oct 10, following a brief delay, and plans to resume manufacturing soon.Endologix Inc says many of the company’s Santa Rosa employees have been adversely impacted by the fire.  Full Article

Endologix announces CE Mark approval for Nellix Endovascular Aneurysm Sealing System
Thursday, 21 Sep 2017 

Sept 21 (Reuters) - Endologix Inc :Endologix announces CE Mark approval for the Nellix Endovascular Aneurysm Sealing System with the refined indications for use.Endologix Inc - ‍Nellix is being studied in U.S. under an Investigational Device Exemption​.  Full Article

Endologix Q2 loss per share $0.20
Wednesday, 2 Aug 2017 

Aug 2 (Reuters) - Endologix Inc :Endologix reports second quarter 2017 financial results.Sees FY 2017 GAAP loss per share $0.91 to $0.95.Q2 loss per share $0.20.Sees FY 2017 revenue $185 million to $190 million.Q2 revenue $48.6 million versus I/B/E/S view $47.6 million.Q2 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $-0.63, revenue view $195.1 million -- Thomson Reuters I/B/E/S.  Full Article